Cargando…

Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial

This trial investigated the efficacy of omega-3 polyunsaturated fatty acid (n-3 PUFA) treatment for improving depressive symptoms and cognitive performance in patients with coronary artery disease (CAD) participating in cardiac rehabilitation. Patients with CAD aged 45 to 80 years were randomized to...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazereeuw, Graham, Herrmann, Nathan, Oh, Paul I., Ma, David W.L., Wang, Cheng Tao, Kiss, Alexander, Lanctôt, Krista L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017271/
https://www.ncbi.nlm.nih.gov/pubmed/27529771
http://dx.doi.org/10.1097/JCP.0000000000000565
_version_ 1782452715042897920
author Mazereeuw, Graham
Herrmann, Nathan
Oh, Paul I.
Ma, David W.L.
Wang, Cheng Tao
Kiss, Alexander
Lanctôt, Krista L.
author_facet Mazereeuw, Graham
Herrmann, Nathan
Oh, Paul I.
Ma, David W.L.
Wang, Cheng Tao
Kiss, Alexander
Lanctôt, Krista L.
author_sort Mazereeuw, Graham
collection PubMed
description This trial investigated the efficacy of omega-3 polyunsaturated fatty acid (n-3 PUFA) treatment for improving depressive symptoms and cognitive performance in patients with coronary artery disease (CAD) participating in cardiac rehabilitation. Patients with CAD aged 45 to 80 years were randomized to receive either 1.9-g/d n-3 PUFA treatment or placebo for 12 weeks. Depressive symptoms were measured using the Hamilton Depression Rating Scale (HAM-D, primary outcome) and the Beck Depression Inventory II (BDI-II). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria were used to identify a depressive episode at baseline. Cognitive performance was measured using a standardized battery for vascular cognitive impairment. In 92 patients (age, 61.7 ± 8.7 y; 76% male, 40% depressed; HAM-D, 6.9 ± 5.9; BDI-II, 12.3 ± 10.9; n = 45 n-3 PUFA, n = 47 placebo), depression decreased (HAM-D, F(3,91) = 2.71 and P = 0.049; BDI-II, F(3,91) = 6.24 and P < 0.01), and cognitive performance improved (attention/processing speed, F(1,91) = 5.57, P = 0.02; executive function, F(1,91) = 14.64, P < 0.01; visuospatial memory, F(1,91) = 4.01, P = 0.04) over cardiac rehabilitation. Omega-3 PUFA treatment increased plasma eicosapentaenoic acid (F(1,29) = 33.29, P < 0.01) and docosahexaenoic acid (F(1,29) = 15.29, P < 0.01) concentrations but did not reduce HAM-D (F(3,91) = 1.59, P = 0.20) or BDI-II (F(3,91) = 0.46, P = 0.50) scores compared with placebo. Treatment did not improve cognitive performance; however, n-3 PUFAs significantly increased verbal memory compared with placebo in a subgroup of nondepressed patients (F(1,54) = 4.16, P = 0.04). This trial suggests that n-3 PUFAs do not improve depressive and associated cognitive symptoms in those with CAD. The possible benefits of n-3 PUFAs for verbal memory may warrant investigation in well-powered studies.
format Online
Article
Text
id pubmed-5017271
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-50172712016-09-26 Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial Mazereeuw, Graham Herrmann, Nathan Oh, Paul I. Ma, David W.L. Wang, Cheng Tao Kiss, Alexander Lanctôt, Krista L. J Clin Psychopharmacol Original Contributions This trial investigated the efficacy of omega-3 polyunsaturated fatty acid (n-3 PUFA) treatment for improving depressive symptoms and cognitive performance in patients with coronary artery disease (CAD) participating in cardiac rehabilitation. Patients with CAD aged 45 to 80 years were randomized to receive either 1.9-g/d n-3 PUFA treatment or placebo for 12 weeks. Depressive symptoms were measured using the Hamilton Depression Rating Scale (HAM-D, primary outcome) and the Beck Depression Inventory II (BDI-II). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria were used to identify a depressive episode at baseline. Cognitive performance was measured using a standardized battery for vascular cognitive impairment. In 92 patients (age, 61.7 ± 8.7 y; 76% male, 40% depressed; HAM-D, 6.9 ± 5.9; BDI-II, 12.3 ± 10.9; n = 45 n-3 PUFA, n = 47 placebo), depression decreased (HAM-D, F(3,91) = 2.71 and P = 0.049; BDI-II, F(3,91) = 6.24 and P < 0.01), and cognitive performance improved (attention/processing speed, F(1,91) = 5.57, P = 0.02; executive function, F(1,91) = 14.64, P < 0.01; visuospatial memory, F(1,91) = 4.01, P = 0.04) over cardiac rehabilitation. Omega-3 PUFA treatment increased plasma eicosapentaenoic acid (F(1,29) = 33.29, P < 0.01) and docosahexaenoic acid (F(1,29) = 15.29, P < 0.01) concentrations but did not reduce HAM-D (F(3,91) = 1.59, P = 0.20) or BDI-II (F(3,91) = 0.46, P = 0.50) scores compared with placebo. Treatment did not improve cognitive performance; however, n-3 PUFAs significantly increased verbal memory compared with placebo in a subgroup of nondepressed patients (F(1,54) = 4.16, P = 0.04). This trial suggests that n-3 PUFAs do not improve depressive and associated cognitive symptoms in those with CAD. The possible benefits of n-3 PUFAs for verbal memory may warrant investigation in well-powered studies. Lippincott Williams & Wilkins 2016-10 2016-08-31 /pmc/articles/PMC5017271/ /pubmed/27529771 http://dx.doi.org/10.1097/JCP.0000000000000565 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Original Contributions
Mazereeuw, Graham
Herrmann, Nathan
Oh, Paul I.
Ma, David W.L.
Wang, Cheng Tao
Kiss, Alexander
Lanctôt, Krista L.
Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
title Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
title_full Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
title_fullStr Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
title_full_unstemmed Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
title_short Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
title_sort omega-3 fatty acids, depressive symptoms, and cognitive performance in patients with coronary artery disease: analyses from a randomized, double-blind, placebo-controlled trial
topic Original Contributions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017271/
https://www.ncbi.nlm.nih.gov/pubmed/27529771
http://dx.doi.org/10.1097/JCP.0000000000000565
work_keys_str_mv AT mazereeuwgraham omega3fattyacidsdepressivesymptomsandcognitiveperformanceinpatientswithcoronaryarterydiseaseanalysesfromarandomizeddoubleblindplacebocontrolledtrial
AT herrmannnathan omega3fattyacidsdepressivesymptomsandcognitiveperformanceinpatientswithcoronaryarterydiseaseanalysesfromarandomizeddoubleblindplacebocontrolledtrial
AT ohpauli omega3fattyacidsdepressivesymptomsandcognitiveperformanceinpatientswithcoronaryarterydiseaseanalysesfromarandomizeddoubleblindplacebocontrolledtrial
AT madavidwl omega3fattyacidsdepressivesymptomsandcognitiveperformanceinpatientswithcoronaryarterydiseaseanalysesfromarandomizeddoubleblindplacebocontrolledtrial
AT wangchengtao omega3fattyacidsdepressivesymptomsandcognitiveperformanceinpatientswithcoronaryarterydiseaseanalysesfromarandomizeddoubleblindplacebocontrolledtrial
AT kissalexander omega3fattyacidsdepressivesymptomsandcognitiveperformanceinpatientswithcoronaryarterydiseaseanalysesfromarandomizeddoubleblindplacebocontrolledtrial
AT lanctotkristal omega3fattyacidsdepressivesymptomsandcognitiveperformanceinpatientswithcoronaryarterydiseaseanalysesfromarandomizeddoubleblindplacebocontrolledtrial